These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1451 related items for PubMed ID: 26093899

  • 1. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK, Kyprianou N.
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [Abstract] [Full Text] [Related]

  • 2. Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer.
    Martin SK, Pu H, Penticuff JC, Cao Z, Horbinski C, Kyprianou N.
    Cancer Res; 2016 Feb 15; 76(4):912-26. PubMed ID: 26645563
    [Abstract] [Full Text] [Related]

  • 3. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A, Kim SH, Hwang C.
    Prostate; 2022 Feb 15; 82(2):182-192. PubMed ID: 34672379
    [Abstract] [Full Text] [Related]

  • 4. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, de Wit R, van Weerden WM.
    Eur Urol; 2015 Jun 15; 67(6):981-985. PubMed ID: 25484141
    [Abstract] [Full Text] [Related]

  • 5. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.
    Eur J Cancer; 2013 Dec 15; 49(18):3821-30. PubMed ID: 24200698
    [Abstract] [Full Text] [Related]

  • 6. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
    Shiota M, Dejima T, Yamamoto Y, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M.
    Cancer Sci; 2018 Oct 15; 109(10):3224-3234. PubMed ID: 30051622
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
    Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC.
    Mol Cancer Ther; 2018 Oct 15; 17(10):2197-2205. PubMed ID: 29891490
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
    Galletti G, Leach BI, Lam L, Tagawa ST.
    Cancer Treat Rev; 2017 Jun 15; 57():16-27. PubMed ID: 28527407
    [Abstract] [Full Text] [Related]

  • 12. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW, Sweeney CJ.
    Proc Natl Acad Sci U S A; 2016 May 31; 113(22):6259-64. PubMed ID: 27185910
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H.
    Nihon Rinsho; 2014 Dec 31; 72(12):2164-9. PubMed ID: 25518352
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
    Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.
    Cancer Res; 2011 Sep 15; 71(18):6019-29. PubMed ID: 21799031
    [Abstract] [Full Text] [Related]

  • 19. Impact of taxanes on androgen receptor signaling.
    Bai S, Zhang BY, Dong Y.
    Asian J Androl; 2019 Sep 15; 21(3):249-252. PubMed ID: 29900882
    [Abstract] [Full Text] [Related]

  • 20. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
    Mout L, van Royen ME, de Ridder C, Stuurman D, van de Geer WS, Marques R, Buck SAJ, French PJ, van de Werken HJG, Mathijssen RHJ, de Wit R, Lolkema MP, van Weerden WM.
    EBioMedicine; 2021 Nov 15; 73():103681. PubMed ID: 34749299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.